The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Apremilast Krka 10 mg film-coated tablets Apremilast Krka 20 mg film-coated tablets Apremilast Krka 30 mg film-coated tablets



KRKA, d.d., Novo mestoPA1347/114/001

Main Information

Trade NameApremilast Krka 10 mg film-coated tablets Apremilast Krka 20 mg film-coated tablets Apremilast Krka 30 mg film-coated tablets
Active SubstancesApremilast
Apremilast
Apremilast
Dosage FormFilm-coated tablet
Licence HolderKRKA, d.d., Novo mesto
Licence NumberPA1347/114/001

Group Information

ATC CodeL04AA32 apremilast

Status

License statusAuthorised
Licence Issued14/06/2024
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Marketing StatusNot marketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back